drugset
drugset / Trial / NCT04668885

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

NCT04668885 ↗

Phase 2 Active not recruiting 13 enrolled Case Comprehensive Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after Hypomethylating Agents (HMA) failure.

Timeline

Start
2021-01-14
Primary completion
2026-01-19
Completion
2027-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject CPX-351 Other / unclassified 7.5 mg/m2 —
Subject CPX-351 Other / unclassified 15 mg/m2 —

Indications

acute myelomonocytic leukemia M4 myelodysplastic syndrome